Hemodynamic Response

2

Review clinical trials related to Hemodynamic Response. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Demedetomidine and Remifentanil in Electroconvulsive Therapy (ECT)

Electroconvulsive therapy (ECT) is a treatment modality that induces therapeutic seizures through electrical stimulation for the management of certain psychiatric disorders. Nearly all ECT procedures are performed under general anesthesia. However, ECT is commonly associated with acute hyperdynamic responses immediately following electrical stimulation, including transient hypertension and tachycardia. These acute hemodynamic changes may pose significant risks, particularly in patients with ischemic heart disease, hypertension, or cerebrovascular disease. Therefore, the hemodynamic response, seizure quality, and recovery profile are critical factors influencing the choice of anesthetic and adjuvant agents. The primary goal of anesthesia for ECT is to maintain hemodynamic stability without compromising seizure duration or quality while ensuring rapid and safe recovery

Participants needed: 24
Trial details
Phase: Phase 4Age: 18-60Biological sex: AllType: InterventionalSponsor: Inonu UniversityUpdated: Sep 29, 2026Locations: 1
Eligibility criteria

Upremedicated ASA I-II (American Society of Anesthesiologists's physical status)... [+1]

refusal to participate, [+8]

Status: Not yet recruiting

Oral Melatonin VS Nebulized Dexmedetomidine Premedication on Attenuation of Hemodynamic Response to Direct Laryngoscopy and Tracheal Intubation in Hypertensive Patients

The aim of this study is to compare the efficacy of oral melatonin versus nebulized dexmedetomidine in attenuating the hemodynamic response to direct laryngoscopy and endotracheal intubation in controlled hypertensive patients prepared for general anesthesia

Participants needed: 70
Trial details
Phase: Phase 2, Phase 3Age: 40-60Biological sex: AllType: InterventionalSponsor: Tanta UniversityUpdated: Apr 20, 2025Locations: 1
Eligibility criteria

Age (40-60) years of both genders. [+3]

Patient refusal to participate in the study. [+7]